Synthesis, antimycobacterial and antibacterial activity of ciprofloxacin derivatives containing a N-substituted benzyl moiety

被引:40
作者
Wang, Shuo [1 ,2 ]
Jia, Xue-Dong [1 ,2 ]
Liu, Ming-Liang [1 ,2 ]
Lu, Yu [3 ]
Guo, Hui-Yuan [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China
[2] Peking Union Med Coll, Beijing 100050, Peoples R China
[3] Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Pharmacol, Beijing 101149, Peoples R China
关键词
Ciprofloxacin derivatives; Synthesis; Antimycobacterial activity; Antibacterial activity; DNA GYRASE; TUBERCULOSIS; FLUOROQUINOLONES; INHIBITION;
D O I
10.1016/j.bmcl.2012.07.040
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report herein the design and synthesis of a series of novel ciprofloxacin (CPFX) derivatives with remarkable improvement in lipophilicity by introducing a substituted benzyl moiety to the N atom on the C-7 piperazine ring of CPFX. Antimycobacterial and antibacterial activity of the newly synthesized compounds was evaluated. Results reveal that compound 4f has good in vitro activity against all of the tested Gram-positive strains including MRSA and MRSE (MICs: 0.06-32 mu g/mL) which is two to eightfold more potent than or comparable to the parent drug CPFX (MICs: 0.25-128 mu g/mL), Gram-negative bacteria P. aeruginosa (MICs: 0.5-4 mu g/mL) and M. tuberculosis H37Rv ATCC 27294 (MIC: 1 mu g/mL). (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5971 / 5975
页数:5
相关论文
共 33 条
[1]   Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones [J].
Anquetin, Guillaume ;
Greiner, Jacques ;
Mahmoudi, Nassira ;
Santillana-Hayat, Maud ;
Gozalbes, Rafael ;
Farhati, Khemais ;
Derouin, Francis ;
Aubry, Alexandra ;
Cambau, Emmanuelle ;
Vierling, Pierre .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (12) :1478-1493
[2]   Mycobacterium tuberculosis DNA gyrase:: Interaction with quinolones and correlation with antimycobacterial drug activity [J].
Aubry, A ;
Pan, XS ;
Fisher, LM ;
Jarlier, V ;
Cambau, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1281-1288
[3]  
Basuri TS, 2011, J PHARM RES, V4, P1294
[4]   Recent advances in bacterial topoisomerase inhibitors [J].
Bradbury, Barton J. ;
Pucci, Michael J. .
CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (05) :574-581
[5]  
[陈孝进 CHEN Xiaojin], 2006, [中华医院感染学杂志, Chinese Journal of Nosocomiology], V16, P216
[6]   Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium [J].
Collins, LA ;
Franzblau, SG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1004-1009
[7]  
CROFTON J, 1997, WHOTB96210REV1
[8]   Synthesis and antibacterial activity of novel fluoroquinolones containing substituted piperidines [J].
Dang, Zhao ;
Yang, Yushe ;
Ji, Ruyun ;
Zhang, Shuhua .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (16) :4523-4526
[9]   Quinolone-mediated bacterial death [J].
Drlica, Karl ;
Malik, Muhammad ;
Kerns, Robert J. ;
Zhaol, Xilin .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (02) :385-392
[10]   Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli [J].
Dwyer, Daniel J. ;
Kohanski, Michael A. ;
Hayete, Boris ;
Collins, James J. .
MOLECULAR SYSTEMS BIOLOGY, 2007, 3 (1)